361 related articles for article (PubMed ID: 23202900)
1. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.
Dimitroulas T; Sandoo A; Kitas GD
Int J Mol Sci; 2012 Sep; 13(10):12315-35. PubMed ID: 23202900
[TBL] [Abstract][Full Text] [Related]
2. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
4. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
5. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
Böger RH; Ron ES
Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
8. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
Szuba A; Podgórski M
Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
11. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk in autoimmune disorders: role of asymmetric dimethylarginine.
Chen XM; Hu CP; Li YJ; Jiang JL
Eur J Pharmacol; 2012 Dec; 696(1-3):5-11. PubMed ID: 23026371
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Böger RH
Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
[TBL] [Abstract][Full Text] [Related]
15. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease.
Franceschelli S; Ferrone A; Pesce M; Riccioni G; Speranza L
Int J Mol Sci; 2013 Dec; 14(12):24412-21. PubMed ID: 24351825
[TBL] [Abstract][Full Text] [Related]
16. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
17. Intraplatelet L-Arginine-Nitric Oxide Metabolic Pathway: From Discovery to Clinical Implications in Prevention and Treatment of Cardiovascular Disorders.
Gawrys J; Gajecki D; Szahidewicz-Krupska E; Doroszko A
Oxid Med Cell Longev; 2020; 2020():1015908. PubMed ID: 32215167
[TBL] [Abstract][Full Text] [Related]
18. The DDAH-ADMA-NOS pathway.
Leiper JM
Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
Cable DG; Celotto AC; Evora PR; Schaff HV
Med Sci Monit; 2009 Sep; 15(9):BR248-53. PubMed ID: 19721392
[TBL] [Abstract][Full Text] [Related]
20. Does ADMA cause endothelial dysfunction?
Cooke JP
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2032-7. PubMed ID: 10978245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]